Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 13/20 | 0.66 |
| ▸ | UGCG | Q16739 | 4/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | MC3R | P41968 | 3/20 | 0.47 |
| ▸ | MC5R | P33032 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21674357 | 1.00 | MC4R (0.66) | MC4RUGCGCYP3A4MC3RMC5R | |
| SCHEMBL16825980 | 0.89 | MC4R (0.69) | MC4RUGCGCYP3A4MC3RMC5R | |
| SCHEMBL16846209 | 0.88 | MC4R (0.58) | MC4RUGCGMC3R | |
| SCHEMBL2795241 | 0.85 | KMT2A (0.52) | MC4RUGCGCYP3A4MC3RMC5R | |
| SCHEMBL4771336 | 0.85 | MC4R (0.72) | MC4RUGCGCYP3A4MC3RMC5R | |
| SCHEMBL4795886 | 0.85 | MC4R (0.72) | MC4RUGCGCYP3A4MC3RMC5R | |
| SCHEMBL16825736 | 0.84 | UGCG (0.71) | MC4RUGCGCYP3A4MC3R | |
| SCHEMBL29868437 | 0.83 | MC4R (0.60) | MC4RUGCGCYP3A4MC3RMC5R | |
| SCHEMBL29868450 | 0.83 | MC4R (0.60) | MC4RUGCGCYP3A4MC3RMC5R | |
| SCHEMBL6730395 | 0.82 | MC4R (0.59) | MC4RUGCGCYP3A4MC3RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082805-B1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INST FOR DRUG DISCOVERY LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2015095701-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | THE INSTITUTE FOR DRUG DELIVERY (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | CMA1, CHIA, AADAC | MC4R 1089/4885UGCG 551/4885CYP3A4 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.